These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11207885)

  • 1. Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice.
    Movig KL; Egberts AC; Lenderink AW; Leufkens HG
    J Am Geriatr Soc; 2001 Feb; 49(2):234-5. PubMed ID: 11207885
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neuropsychiatric adverse effects attributed to use of oxybutynin].
    t'Veld BA; Kwee-Zuiderwijk WJ; van Puijenbroek EP; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(11):590-2. PubMed ID: 9623118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
    Von Zweigbergk M; Nordin B; Jonsson S
    Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe anticholinergic drug-induced delirium in a young adult after renal transplantation.
    Götz AK; Reinhold SW; Szecsey A; Banas B; Krämer BK
    Transpl Int; 2009 Feb; 22(2):249-50. PubMed ID: 18786150
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.
    Thüroff JW; Bunke B; Ebner A; Faber P; de Geeter P; Hannappel J; Heidler H; Madersbacher H; Melchior H; Schäfer W
    J Urol; 1991 Apr; 145(4):813-6; discussion 816-7. PubMed ID: 2005707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxybutynin: is it safe?
    Baigrie RJ; Kelleher JP; Fawcett DP; Pengelly AW
    Br J Urol; 1988 Oct; 62(4):319-22. PubMed ID: 3191355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New adverse effect of oxybutynin: "night terror".
    Valsecia ME; Malgor LA; Espíndola JH; Carauni DH
    Ann Pharmacother; 1998 Apr; 32(4):506. PubMed ID: 9562151
    [No Abstract]   [Full Text] [Related]  

  • 9. Is attempting suicide an adverse effect of oxybutynin in a child with enuresis nocturna?
    Coskun S; Yüksel H; Onag A
    Pediatr Emerg Care; 2001 Oct; 17(5):398. PubMed ID: 11673723
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute-angle closure glaucoma as a side-effect of oxybutynin.
    Sung VC; Corridan PG
    Br J Urol; 1998 Apr; 81(4):634-5. PubMed ID: 9598644
    [No Abstract]   [Full Text] [Related]  

  • 11. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation.
    Dahm TL; Ostri P; Kristensen JK; Walter S; Frimodt-Møller C; Rasmussen RB; Nøhr M; Alexander N
    Urol Int; 1995; 55(4):205-8. PubMed ID: 8588267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia.
    Kasabian NG; Vlachiotis JD; Lais A; Klumpp B; Kelly MD; Siroky MB; Bauer SB
    J Urol; 1994 Apr; 151(4):944-5. PubMed ID: 8126833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adverse effects of oxybutynin chloride (Ditropan). Evaluation of the official survey of Regional Pharmacovigilance Centers].
    Jonville AP; Dutertre JP; Autret E; Barbellion M
    Therapie; 1992; 47(5):389-92. PubMed ID: 1299977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxybutynin-induced reflux esophagitis.
    Lee M; Sharifi R
    DICP; 1990 Jun; 24(6):583-5. PubMed ID: 2360335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of oxybutynin in urological practice.
    Kirkali Z; Whitaker RH
    Int Urol Nephrol; 1987; 19(4):385-91. PubMed ID: 3429165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxybutynin does not affect cyclosporin blood levels.
    Springate JE
    Ther Drug Monit; 2001 Apr; 23(2):155-6. PubMed ID: 11294516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxybutynin dependence: a case presentation.
    Mutlu EA
    Turk Psikiyatri Derg; 2011; 22(2):131-2. PubMed ID: 21780343
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exaggerated neurological side-effects of oral and intravesical oxybutynin in a patient with multiple sclerosis.
    Vaidyanathan S; Krishnan KR; Soni BM; Fraser MH
    Spinal Cord; 1997 Mar; 35(3):190-1. PubMed ID: 9076875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.